Rosenberg R, Nekarda H, Zimmermann F, Becker K, Lordick F, Hofler H, Molls M, Siewert J R
Chirurgische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
J Surg Oncol. 2008 Jan 1;97(1):8-13. doi: 10.1002/jso.20844.
Recent studies showed improved local control after preoperative radiochemotherapy (RCTX) in patients with locally advanced rectal carcinoma, but failed to demonstrate a survival benefit. Our aims were to determine outcome and impact of histopathological response after preoperative RCTX.
One hundred four patients with uT3 rectal carcinoma were treated with preoperative RCTX of 45 Gy and continuous 5-FU infusion between 1997 and 2001 (group I). Histopathological response was evaluated in all specimens after tumor resection. Group II consisted of 114 patients with uT3 rectal carcinoma treated with postoperative RCTX between 1988 and 1997.
Group I showed a 6.1% 5-year local recurrence rate compared to 15.3% in group II (P = 0.023). Overall survival rates did not differ significantly between both groups (P = 0.225). Histopathological responders had a significantly improved 5-year overall survival with 89.1 (7.8)% compared to 68.7 (6.7)% of the non-responders (P = 0.008) and were identified as an independent prognostic factor.
Significant improvement of overall survival was observed for histopathological tumor responders after neoadjuvant radiochemotherapy. Our protocol of preoperative radiochemotherapy confirms the results of the multi-center studies in regard to local control and overall survival.
近期研究表明,局部晚期直肠癌患者术前放化疗(RCTX)后局部控制情况有所改善,但未显示出生存获益。我们的目的是确定术前RCTX后组织病理学反应的结果及影响。
1997年至2001年期间,104例uT3期直肠癌患者接受了45 Gy的术前RCTX及持续5-氟尿嘧啶输注(I组)。肿瘤切除后对所有标本进行组织病理学反应评估。II组由1988年至1997年期间接受术后RCTX治疗的114例uT3期直肠癌患者组成。
I组5年局部复发率为6.1%,而II组为15.3%(P = 0.023)。两组的总生存率无显著差异(P = 0.225)。组织病理学反应者的5年总生存率显著提高,为89.1(7.8)%,而非反应者为68.7(6.7)%(P = 0.008),且被确定为独立的预后因素。
新辅助放化疗后组织病理学肿瘤反应者的总生存率有显著提高。我们的术前放化疗方案在局部控制和总生存方面证实了多中心研究的结果。